FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warrants issued under its September 2023 private placement have been exercised for Series E preferred stock, convertible into the company's common stock, by the participants of the previous financing, led by Rosalind Advi ...

The new warrants purchased by investors include Tranche A, B and C. The Tranche A warrants provide gross proceeds up to approximately $17.0 million based on the exercise price of $2.52, which was the closing market price of the Company's common stock on July 19, 2024, and include a 10-trading-day trigger for exercise following Cellectar's public announcement of the Food and Drug Administration (FDA) having assigned a Prescription Drug User Fee Act goal date for review of iopofosine I 131. The Tranche B Warr ...

The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and full results. Details are as follows: A replay of the conference call will be available on the Events section of the company's investor relations website. Waldenstrom's macroglobulinemia is a B-cell malignancy characterized by bone marrow infiltration of clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. T ...

The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and full results. Details are as follows: A replay of the conference call will be available on the Events section of the company's investor relations website. Waldenstrom's macroglobulinemia is a B-cell malignancy characterized by bone marrow infiltration of clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. T ...

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin's Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. "We are excited to partner with Cellectar Biosciences to evaluate iopofosine in patients with mycosis fungoides," said Dr. Steven T. Rosen, executive vice president and director emeritus, Comprehensive Cancer Center and Beckman Research Institute of City of Hope. "Its unique delivery platform targeting all tumor ...

Topline Summary and Update Financial Overview As of their Q1 filing, CLRB held $41.4 million in current assets, made up mostly of $40.0 million in cash and equivalents. Their operating expenses, or cash burn, for the quarter reached $12.0 million. After recognizing an addition $9.9 million in losses due to valuation of their warrants, the net loss for the quarter was $21.6 million. Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a radiopharmaceutical-focused developmental biotech training their sites on a firs ...

Iopofosine I 131: U.S. WM Shares By Line of Therapy No Established Standard of Care Across All Lines of Therapy8 | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants James Caruso - President and Chief Executive Officer Andrei Shustov - Senior Vice President, Medical Jarrod Longcor - Chief Operating Officer Shane Lea - Chief Commercial Officer Chad Kolean - Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Jeff Jones - Oppenheimer Jonathan Aschoff - ROTH MKM Operator Good morning and welcome to Cellectar Biosciences Fir ...

Exhibit 99.1 Management to host a conference call today at 8:30 am ET FLORHAM PARK, N.J., May 14, 2024 – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. First Quarter and Recent Corporate Highlights · Reported a complete remission rate of 64% and overall response ...

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. "We plan to announce data from our CLOVER WaM pivotal study e ...